ARS-1630 is a potent and selective allosteric inhibitor of the oncogenic PI3Kα H1047R mutant kinase. It is primarily used in research and development within the pharmaceutical industry, particularly in the field of oncology. It is investigated for its potential as a therapeutic agent targeting the PI3K/AKT/mTOR pathway involved in cancer progression. Researchers focus on its ability to inhibit the mutant PI3Kα enzyme that plays a critical role in tumor growth and metastasis. Its application is mostly confined to preclinical studies, where it is tested in vitro and in vivo to evaluate its efficacy, safety, and mechanism of action. The compound is also utilized in biomarker studies to understand its impact on cellular processes and its potential for combination therapies with other anticancer drugs.